<span id="midArticle_start"/> The following are some of themain factors expected to affect Swiss stocks on Tuesday:
<span id="midArticle_0"/>
<span id="midArticle_1"/>COMPANY STATEMENTS
<span id="midArticle_2"/>* Nestle USA said it would remove artificialflavours and reduce sodium in frozen pizza and snack products bythe end of the year.
<span id="midArticle_3"/>* Novartis said CTL019 data showed its potentialin the treatment of specific types of hard-to-treat non-hodgkinlymphoma and highlight preliminary safety and efficacy data forthe medicine in other indications.
<span id="midArticle_4"/> <span class="first-article-divide"/>* Novartis said new one-year data for secukinumab,the first IL-17A inhibitor to show significant improvement inankylosing spondylitis (AS) signs and symptoms, was to bepresented at European League Against Rheumatism meeting (EULAR).
<span id="midArticle_5"/>* Roche said it would collaborate with Amgen on aphase 1b study to evaluate the safety and efficacy of talimogenelaherparepvec, Amgen's investigational oncolytic immunotherapy,in combination with Roche's investigational anti-PDL1 therapyatezolizumab, in patients with triple-negative breast cancer andcolorectal cancer with liver metastases.
<span id="midArticle_6"/> <span class="second-article-divide"/>* Meyer Burger said it had been selected by LerriSolar Technology to supply MB PERC upgrade cell solution and PVmeasurement technology. The order volume is around 16.5 millionSwiss francs, the firm said.
<span id="midArticle_7"/>* Nobel Biocare announced the cancellation of itspublicly held shares and de-listing from Six Swiss Exchange asof June 10.
<span id="midArticle_8"/> <span class="third-article-divide"/>
<span id="midArticle_9"/>ECONOMY
<span id="midArticle_10"/>(Reporting by Zurich newsroom)
<span id="midArticle_11"/>
<span id="midArticle_0"/>
<span id="midArticle_1"/>COMPANY STATEMENTS
<span id="midArticle_2"/>* Nestle USA said it would remove artificialflavours and reduce sodium in frozen pizza and snack products bythe end of the year.
<span id="midArticle_3"/>* Novartis said CTL019 data showed its potentialin the treatment of specific types of hard-to-treat non-hodgkinlymphoma and highlight preliminary safety and efficacy data forthe medicine in other indications.
<span id="midArticle_4"/> <span class="first-article-divide"/>* Novartis said new one-year data for secukinumab,the first IL-17A inhibitor to show significant improvement inankylosing spondylitis (AS) signs and symptoms, was to bepresented at European League Against Rheumatism meeting (EULAR).
<span id="midArticle_5"/>* Roche said it would collaborate with Amgen on aphase 1b study to evaluate the safety and efficacy of talimogenelaherparepvec, Amgen's investigational oncolytic immunotherapy,in combination with Roche's investigational anti-PDL1 therapyatezolizumab, in patients with triple-negative breast cancer andcolorectal cancer with liver metastases.
<span id="midArticle_6"/> <span class="second-article-divide"/>* Meyer Burger said it had been selected by LerriSolar Technology to supply MB PERC upgrade cell solution and PVmeasurement technology. The order volume is around 16.5 millionSwiss francs, the firm said.
<span id="midArticle_7"/>* Nobel Biocare announced the cancellation of itspublicly held shares and de-listing from Six Swiss Exchange asof June 10.
<span id="midArticle_8"/> <span class="third-article-divide"/>
<span id="midArticle_9"/>ECONOMY
<span id="midArticle_10"/>(Reporting by Zurich newsroom)
<span id="midArticle_11"/>
via Smart Health Shop Forum http://ift.tt/1AHKJJY
No comments:
Post a Comment